Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations

Splice-modulating antisense oligonucleotides (ASOs) offer treatment options for rare neurological diseases, including those with very rare mutations, where patient-specific, individualized ASOs have to be developed. Inspired by the development of milasen, the 1 Mutation 1 Medicine (1M1M) and Dutch C...

Descripción completa

Detalles Bibliográficos
Autores principales: Aartsma-Rus, Annemieke, van Roon-Mom, Willeke, Lauffer, Marlen, Siezen, Christine, Duijndam, Britt, Coenen-de Roo, Tineke, Schüle, Rebecca, Synofzik, Matthis, Graessner, Holm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019362/
https://www.ncbi.nlm.nih.gov/pubmed/36669889
http://dx.doi.org/10.1261/rna.079540.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019362/
https://www.ncbi.nlm.nih.gov/pubmed/36669889
http://dx.doi.org/10.1261/rna.079540.122

Ejemplares similares